ibudilast has been researched along with Drug Withdrawal Symptoms in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ibudilast (AV-411) is a non-selective phosphodiesterase inhibitor that is also known to suppress glial cell activation." | 2.44 | Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. ( Hutchinson, MR; Johnson, KW; Ledeboer, A; Watkins, LR, 2007) |
| "Ibudilast was well tolerated; no serious adverse events occurred during the study." | 1.43 | The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. ( Comer, SD; Cooper, ZD; Glass, A; Johnson, KW; Jones, JD; Manubay, JM; Martinez, DM; Pavlicova, M; Saccone, PA; Sullivan, MA; Vosburg, SK, 2016) |
| "Morphine or vehicle was administered s." | 1.35 | The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release. ( Bland, ST; Hutchinson, MR; Johnson, KW; Maier, SF; Watkins, LR, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cooper, ZD | 1 |
| Johnson, KW | 4 |
| Pavlicova, M | 1 |
| Glass, A | 1 |
| Vosburg, SK | 1 |
| Sullivan, MA | 1 |
| Manubay, JM | 1 |
| Martinez, DM | 1 |
| Jones, JD | 1 |
| Saccone, PA | 1 |
| Comer, SD | 1 |
| Hutchinson, MR | 3 |
| Lewis, SS | 1 |
| Coats, BD | 1 |
| Skyba, DA | 1 |
| Crysdale, NY | 1 |
| Berkelhammer, DL | 1 |
| Brzeski, A | 1 |
| Northcutt, A | 1 |
| Vietz, CM | 1 |
| Judd, CM | 1 |
| Maier, SF | 2 |
| Watkins, LR | 3 |
| Bland, ST | 1 |
| Ledeboer, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Safety, Tolerability and Preliminary Efficacy of AV411, a Glial Activation Inhibitor, in Heroin Abusers Under Conditions of Morphine Maintenance and Withdrawal[NCT00723177] | Phase 2 | 30 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measures severity of opioid withdrawal in opioid dependent populations (0-64). Larger values indicate more severe withdrawal. (NCT00723177)
Timeframe: Measured at the end of each two-week maintenance period (i.e., Placebo, Low AV411, High AV411).
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 16 |
| Low-dose AV411 | 4 |
| High-dose AV411 | 24 |
The McGill Pain Questionnaire (Melzack, 1987) was used to assess pain experience immediately following the immersion of the hand in 4 degree Celsius water. Scores were added across all 15 items to generate a sum score, which ranged between 15 and 60. Larger scores indicate greater pain levels. (NCT00723177)
Timeframe: Measured at the end of each AV411 of the three two-week maintenance periods
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 40 |
| Low-dose AV411 | 42 |
| High-dose AV411 | 38 |
1 review available for ibudilast and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 2007 |
3 other studies available for ibudilast and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers.
Topics: Adult; Female; Humans; Male; Middle Aged; Opioid-Related Disorders; Phosphodiesterase Inhibitors; Py | 2016 |
Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast).
Topics: Analgesia; Analgesics, Opioid; Animals; Anti-Bacterial Agents; Brain; Bronchodilator Agents; Dose-Re | 2009 |
The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release.
Topics: Analysis of Variance; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Dopamine; Dru | 2009 |